<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html>
  <head>
    <title>Parkinson disease</title>
    <meta name="generator" content="muse.el">
    <meta http-equiv="Content-Type"
          content="text/html; charset=iso-8859-1">
    
    
<link rel="stylesheet" type="text/css" charset="utf-8" media="all" href="common.css" />
<link rel="stylesheet" type="text/css" charset="utf-8" media="screen" href="screen.css" />
<link rel="stylesheet" type="text/css" charset="utf-8" media="print" href="~print.css" />

  </head>
  <body>

    <!-- Page published by Emacs Muse begins here -->
<h2><a href="Parkinson%20disease.html">Parkinson disease</a></h2>

<h3>Definition</h3>

<p class="first">impaired movement (<a href="hypokinetic.html">hypokinetic</a>)</p>

<blockquote>
<p class="quoted">also disturbances of affect, behavior and cognition</p>
</blockquote>



<h3>See also</h3>

<blockquote>
<p class="quoted"><a href="motor%20disorders.html">motor disorders</a></p>
</blockquote>

<blockquote>
<p class="quoted"><a href="Huntington%20disease.html">Huntington disease</a></p>
</blockquote>

<blockquote>
<p class="quoted"><a href="basal%20ganglia.html">basal ganglia</a></p>
</blockquote>

<blockquote>
<p class="quoted"><a href="dopamine.html">dopamine</a></p>
</blockquote>



<h3>Causation</h3>

<p class="first">caused by loss of dopaminergic neurons in the <a href="pars%20compacta.html">pars compacta</a>
of <a href="substantia%20nigra.html">substantia nigra</a></p>

<blockquote>
<p class="quoted"><a href="acetylcholine.html">acetylcholine</a> too high, and <a href="dopamine.html">dopamine</a> too low in the
<a href="striatum.html">striatum</a></p>
</blockquote>

<blockquote>
<p class="quoted">what does the <a href="acetylcholine.html">acetylcholine</a> in the <a href="striatum.html">striatum</a> do???</p>
</blockquote>

<blockquote>
<p class="quoted"><a href="direct%20pathway.html">direct pathway</a> activity is reduced, and <a href="indirect%20pathway.html">indirect pathway</a>
activity is increased</p>
</blockquote>

<blockquote>
<p class="quoted">i.e. the <a href="indirect%20pathway.html">indirect pathway</a> is stronger than the <a href="direct%20pathway.html">direct pathway</a></p>
</blockquote>

<blockquote>
<p class="quoted">so the <a href="thalamus.html">thalamus</a> is inhibited much more</p>
</blockquote>

<p>loss of <a href="dopamine.html">dopamine</a> in the <a href="putamen.html">putamen</a> is greatest on side
contralateral to the more affected side</p>

<blockquote>
<p class="quoted">this might be why you get involuntary <a href="saccades.html">saccades</a> to the
contralateral side (see <a href="oculomotor%20circuit.html">oculomotor circuit</a>)!</p>
</blockquote>



<h3>Clinical</h3>

<h4>Symptoms</h4>

<p class="first">akinesia and bradykinesia (see <a href="hypokinetic.html">hypokinetic</a>) are both seen in
Parkinson's disease</p>

<p>difficulty initiating movements &amp; stopping them once started</p>

<p>tremor (at rest)</p>

<p>rigidity (hypertonia in flexors &amp; extensors)</p>

<p>loss of &quot;associated movements&quot; (e.g., swinging arms while
walking)</p>

<p><a href="Parkinson%20disease.html">Parkinson disease</a> patients get hallucinations and tics
(e.g. De Niro in Awakenings)</p>



<h4><a href="L-DOPA.html">L-DOPA</a> treatment</h4>
<a name="L-DOPA" id="L-DOPA"></a>
see <a href="L-DOPA.html">L-DOPA</a>

<p><a href="dopamine.html">dopamine</a> cannot cross <a href="blood-brain%20barrier.html">blood-brain barrier</a></p>

<blockquote>
<p class="quoted">use <a href="L-DOPA.html">L-DOPA</a> (synthetic precursor to <a href="dopamine.html">dopamine</a>) instead</p>
</blockquote>

<blockquote>
<p class="quoted">can cross the <a href="blood-brain%20barrier.html">blood-brain barrier</a> and be converted to
<a href="dopamine.html">dopamine</a></p>
</blockquote>

<blockquote>
<p class="quoted">benefits begin to wane after about 5 years</p>
</blockquote>

<blockquote>
<p class="quoted">over-treatment can induce choreiform ('dance-like')
movements (see <a href="hyperkinetic.html">hyperkinetic</a>)</p>
</blockquote>



<h4>MPTP</h4>

<p class="first">William Langston discovered that drug addicts exposed to
MPTP develop a profound Parkinsonian state</p>

<p>besides the increased tonic output of the internal globus
pallidus, MPTP monkeys also show changes in the pattern of
phasic discharge</p>

<blockquote>
<p class="quoted">synchronized oscillatory discharge from the <a href="basal%20ganglia.html">basal ganglia</a>
may be causing the tremors</p>
</blockquote>



<h4>Lesioning</h4>

<p class="first">excessive activity in the <a href="indirect%20pathway.html">indirect pathway</a> at the
<a href="subthalamic%20nucleus.html">subthalamic nucleus</a> seems to be a big factor in <a href="Parkinson%20disease.html">Parkinson disease</a>
signs</p>

<blockquote>
<p class="quoted">lesioning the sensorimotor bit of the <a href="subthalamic%20nucleus.html">subthalamic nucleus</a>
or the <a href="internal%20globus%20pallidus.html">internal globus pallidus</a> seems to really improve
MPTP-treated monkeys</p>
</blockquote>

<blockquote>
<p class="quoted">so pallidotomy is sometimes used for helping medically
intractable cases of <a href="Parkinson%20disease.html">Parkinson disease</a></p>
</blockquote>

<blockquote>
<p class="quoted">apparently Michael J Fox had a pallidotomy</p>
</blockquote>




<h3>Simulations</h3>
<a name="simulations" id="simulations"></a>
simulated as: low levels of <a href="dopamine.html">dopamine</a> in the <a href="pars%20compacta.html">pars compacta</a>

<blockquote>
<p class="quoted">diminished tonic <a href="dopamine.html">dopamine</a>, and diminished (positive)
phasic <a href="dopamine.html">dopamine</a> bursts</p>
</blockquote>

<blockquote>
<p class="quoted">favours the no-go pathway - fits with Parkinson's patients'
troubles initiating movements</p>
</blockquote>

<p>so Frank predicted they'd have problems <a href="learning.html">learning</a> from
positive reinforcement</p>

<blockquote>
<p class="quoted">however, they can still show the phasic <a href="dopamine.html">dopamine</a> <em>decreases</em></p>
</blockquote>

<blockquote>
<p class="quoted">though perhaps with a slightly more limited range</p>
</blockquote>

<blockquote>
<p class="quoted">so their capacity for <a href="learning.html">learning</a> from <em>negative</em>
reinforcement should be relatively spared</p>
</blockquote>

<p>interesting control group - Parkinson's patients taking
<a href="L-DOPA.html">L-DOPA</a></p>

<blockquote>
<p class="quoted">should have <em>more</em> <a href="dopamine.html">dopamine</a> in their system than normal
controls</p>
</blockquote>

<blockquote>
<p class="quoted">should have more tonic <a href="dopamine.html">dopamine</a>, and so diminished
capacity for phasic <a href="dopamine.html">dopamine</a> dips</p>
</blockquote>

<blockquote>
<p class="quoted">should have problems <a href="learning.html">learning</a> from <em>negative</em> reinforcement</p>
</blockquote>

<blockquote>
<p class="quoted">but should have phasic <a href="dopamine.html">dopamine</a> <em>increases</em> - spared
positive reinforcement <a href="learning.html">learning</a></p>
</blockquote>

<p>Frank, ...  &amp; O'Reilly (Science, 2005)</p>

<p>two ways to solve the AB discrimination</p>

<ul>
<li>associate A with go</li>
<li>associate B with no-go</li>
</ul>

<p>train on A vs B discrimination</p>

<blockquote>
<p class="quoted">test A vs C, D, E, F</p>
</blockquote>

<blockquote>
<p class="quoted">compute the average probability of choosing A</p>
</blockquote>

<blockquote>
<p class="quoted">if A is strongly associated with go, then subjects will
show a strong tendency to choose A</p>
</blockquote>

<blockquote>
<p class="quoted">test B vs C, D, E, F</p>
</blockquote>

<blockquote>
<p class="quoted">if B is strongly associated with no-go, then subjects
will show a strong tendency to choose against B</p>
</blockquote>

<p>so <a href="Parkinson%20disease.html">Parkinson disease</a> patients will rely primarily on no-go
<a href="learning.html">learning</a></p>

<ul>
<li>normal tendency to choose against B</li>
<li>impaired tendency to choose A</li>
</ul>

<p>and vice versa for the <a href="L-DOPA.html">L-DOPA</a> patients</p>

<p>low tonic <a href="dopamine.html">dopamine</a> - operationalized by lower tonic input to
<a href="pars%20compacta.html">pars compacta</a> units</p>

<blockquote>
<p class="quoted">parameters are out of the range that the system was
designed for</p>
</blockquote>

<blockquote>
<p class="quoted">you start to see regular oscillations between external
<a href="globus%20pallidus.html">globus pallidus</a> and <a href="subthalamic%20nucleus.html">subthalamic nucleus</a>, as a result of
all the feedback loops</p>
</blockquote>

<blockquote>
<p class="quoted">could be a neural substrate of tremors</p>
</blockquote>

<p>is the no-go pathway necessary?</p>

<blockquote>
<p class="quoted">it greatly enhances performance in the model</p>
</blockquote>

<blockquote>
<p class="quoted">it's useful to have the ability to specifically say
'stimulus X should not trigger response Y'</p>
</blockquote>

<p>lots of complex machinery - aimed at instilling a strong
negative <a href="bias.html">bias</a> on initiating actions</p>



<h3>History</h3>

<p class="first">first described by James Parkinson in 1817</p>

<p>affects &lt;=1m people in the US</p>



<h3>Questions</h3>

<p class="first">can you have <a href="Parkinson%20disease.html">Parkinson disease</a> and <a href="Huntington%20disease.html">Huntington disease</a> at the
same time???</p>

<blockquote>
<p class="quoted">if not, why do Parkinsonian patients tremor???</p>
</blockquote>

<blockquote>
<p class="quoted">see the MPTP section</p>
</blockquote>

<blockquote>
<p class="quoted">don't think you could have them both - because they're all
about the ratio of the <a href="direct%20pathway.html">direct pathway</a> and <a href="indirect%20pathway.html">indirect pathway</a></p>
</blockquote>




<!-- Page published by Emacs Muse ends here --> 

<hr>

<script language="javascript" src="footer.js">

  </body>
</html>
